Cargando…
Bevacizumab-Induced Pneumonitis in a Patient With Metastatic Colon Cancer: A Case Report
Bevacizumab is a vascular endothelial growth factor–directed humanized monoclonal antibody used to treat many types of cancer and some eye diseases. Due to inhibition of angiogenesis, many adverse reactions such as bowel necrosis, nasal septal perforation, and renal thrombotic microangiopathy have b...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297475/ https://www.ncbi.nlm.nih.gov/pubmed/32595283 http://dx.doi.org/10.1177/1179548420929285 |
_version_ | 1783547012128440320 |
---|---|
author | Pervaiz, Sami Homsy, Sylvester Narula, Naureen Ngu, Sam Elsayegh, Dany |
author_facet | Pervaiz, Sami Homsy, Sylvester Narula, Naureen Ngu, Sam Elsayegh, Dany |
author_sort | Pervaiz, Sami |
collection | PubMed |
description | Bevacizumab is a vascular endothelial growth factor–directed humanized monoclonal antibody used to treat many types of cancer and some eye diseases. Due to inhibition of angiogenesis, many adverse reactions such as bowel necrosis, nasal septal perforation, and renal thrombotic microangiopathy have been described. However, its association with interstitial pneumonitis is scarcely reported in the literature. We report a case of a 79-year-old woman with metastatic colon cancer who presented with cough and dyspnea on exertion the day after initiation of bevacizumab. She was found to have bilateral airspace opacities on imaging. Infectious and cardiogenic etiologies of dyspnea were ruled out. Due to the temporal relationship with the initiation of chemotherapy, she was suspected to have developed bevacizumab-induced interstitial pneumonitis. She improved rapidly with high-dose steroids. Follow-up imaging showed resolution of infiltrates. This is the first reported case in the literature that directly links bevacizumab to interstitial pneumonitis. |
format | Online Article Text |
id | pubmed-7297475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-72974752020-06-25 Bevacizumab-Induced Pneumonitis in a Patient With Metastatic Colon Cancer: A Case Report Pervaiz, Sami Homsy, Sylvester Narula, Naureen Ngu, Sam Elsayegh, Dany Clin Med Insights Circ Respir Pulm Med Case Report Bevacizumab is a vascular endothelial growth factor–directed humanized monoclonal antibody used to treat many types of cancer and some eye diseases. Due to inhibition of angiogenesis, many adverse reactions such as bowel necrosis, nasal septal perforation, and renal thrombotic microangiopathy have been described. However, its association with interstitial pneumonitis is scarcely reported in the literature. We report a case of a 79-year-old woman with metastatic colon cancer who presented with cough and dyspnea on exertion the day after initiation of bevacizumab. She was found to have bilateral airspace opacities on imaging. Infectious and cardiogenic etiologies of dyspnea were ruled out. Due to the temporal relationship with the initiation of chemotherapy, she was suspected to have developed bevacizumab-induced interstitial pneumonitis. She improved rapidly with high-dose steroids. Follow-up imaging showed resolution of infiltrates. This is the first reported case in the literature that directly links bevacizumab to interstitial pneumonitis. SAGE Publications 2020-06-15 /pmc/articles/PMC7297475/ /pubmed/32595283 http://dx.doi.org/10.1177/1179548420929285 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Pervaiz, Sami Homsy, Sylvester Narula, Naureen Ngu, Sam Elsayegh, Dany Bevacizumab-Induced Pneumonitis in a Patient With Metastatic Colon Cancer: A Case Report |
title | Bevacizumab-Induced Pneumonitis in a Patient With Metastatic Colon Cancer: A Case Report |
title_full | Bevacizumab-Induced Pneumonitis in a Patient With Metastatic Colon Cancer: A Case Report |
title_fullStr | Bevacizumab-Induced Pneumonitis in a Patient With Metastatic Colon Cancer: A Case Report |
title_full_unstemmed | Bevacizumab-Induced Pneumonitis in a Patient With Metastatic Colon Cancer: A Case Report |
title_short | Bevacizumab-Induced Pneumonitis in a Patient With Metastatic Colon Cancer: A Case Report |
title_sort | bevacizumab-induced pneumonitis in a patient with metastatic colon cancer: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297475/ https://www.ncbi.nlm.nih.gov/pubmed/32595283 http://dx.doi.org/10.1177/1179548420929285 |
work_keys_str_mv | AT pervaizsami bevacizumabinducedpneumonitisinapatientwithmetastaticcoloncanceracasereport AT homsysylvester bevacizumabinducedpneumonitisinapatientwithmetastaticcoloncanceracasereport AT narulanaureen bevacizumabinducedpneumonitisinapatientwithmetastaticcoloncanceracasereport AT ngusam bevacizumabinducedpneumonitisinapatientwithmetastaticcoloncanceracasereport AT elsayeghdany bevacizumabinducedpneumonitisinapatientwithmetastaticcoloncanceracasereport |